Han Hsi Wong, Elena Cojocaru, James Watkins, Sujil James, Tony Aloysius, Jennifer Harrington, Gail Horan, Helen Hatcher
{"title":"辐射诱发的乳腺血管肉瘤:一家地区治疗中心的回顾性分析。","authors":"Han Hsi Wong, Elena Cojocaru, James Watkins, Sujil James, Tony Aloysius, Jennifer Harrington, Gail Horan, Helen Hatcher","doi":"10.1007/s12282-023-01535-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radiation-induced angiosarcoma (RIA) is an uncommon but morbid complication after radiotherapy for breast cancer.</p><p><strong>Methods: </strong>Retrospective analysis of breast RIA patients at Cambridge University Hospital (CUH), a regional treatment centre in the East of England.</p><p><strong>Results: </strong>22 patients were identified between 2010 and 2022. Median age of diagnosis was 65 years (range 41-78). Median time from breast radiotherapy to RIA diagnosis was 6.5 years (range 2.4-16.0)-this interval has decreased over the last 24 years (r<sup>2</sup> = 0.6601). 9% had metastasis at presentation. All patients underwent surgery (55% at CUH, 45% at local hospitals). 27% received peri-operative pegylated liposomal doxorubicin in the first-line setting. 62% relapsed following their primary curative-intent treatments after a median of 28 months. Metastases occurred in 36%, the commonest sites being lung (100%) and lymph node (50%). 2-year and 5-year overall survival (OS) rates for all patients were 73% and 60%, respectively. No correlation between progression-free survival (PFS) and OS was found with tumour size, margin, peri-operative chemotherapy, and whether surgery was performed at CUH. Patients with multifocal disease on their breasts had shorter PFS following surgery compared to single-lesion disease (median 10 vs 65 months; HR = 4.359 [95% CI 1.342-14.16]; P = 0.0143). Patients aged > 72 years had a median OS of 45 months vs 102 months for those ≤ 72 years (HR = 7.129 [95% CI 1.646-30.88]; P = 0.0086).</p><p><strong>Conclusion: </strong>RIA has high rates of recurrence and mortality and appears to be occurring sooner after breast radiotherapy. Further studies on its pathogenesis and effective treatment are warranted.</p>","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":" ","pages":"272-282"},"PeriodicalIF":4.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre.\",\"authors\":\"Han Hsi Wong, Elena Cojocaru, James Watkins, Sujil James, Tony Aloysius, Jennifer Harrington, Gail Horan, Helen Hatcher\",\"doi\":\"10.1007/s12282-023-01535-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Radiation-induced angiosarcoma (RIA) is an uncommon but morbid complication after radiotherapy for breast cancer.</p><p><strong>Methods: </strong>Retrospective analysis of breast RIA patients at Cambridge University Hospital (CUH), a regional treatment centre in the East of England.</p><p><strong>Results: </strong>22 patients were identified between 2010 and 2022. Median age of diagnosis was 65 years (range 41-78). Median time from breast radiotherapy to RIA diagnosis was 6.5 years (range 2.4-16.0)-this interval has decreased over the last 24 years (r<sup>2</sup> = 0.6601). 9% had metastasis at presentation. All patients underwent surgery (55% at CUH, 45% at local hospitals). 27% received peri-operative pegylated liposomal doxorubicin in the first-line setting. 62% relapsed following their primary curative-intent treatments after a median of 28 months. Metastases occurred in 36%, the commonest sites being lung (100%) and lymph node (50%). 2-year and 5-year overall survival (OS) rates for all patients were 73% and 60%, respectively. No correlation between progression-free survival (PFS) and OS was found with tumour size, margin, peri-operative chemotherapy, and whether surgery was performed at CUH. Patients with multifocal disease on their breasts had shorter PFS following surgery compared to single-lesion disease (median 10 vs 65 months; HR = 4.359 [95% CI 1.342-14.16]; P = 0.0143). Patients aged > 72 years had a median OS of 45 months vs 102 months for those ≤ 72 years (HR = 7.129 [95% CI 1.646-30.88]; P = 0.0086).</p><p><strong>Conclusion: </strong>RIA has high rates of recurrence and mortality and appears to be occurring sooner after breast radiotherapy. Further studies on its pathogenesis and effective treatment are warranted.</p>\",\"PeriodicalId\":56083,\"journal\":{\"name\":\"Breast Cancer\",\"volume\":\" \",\"pages\":\"272-282\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12282-023-01535-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/12/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12282-023-01535-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:放疗诱发血管肉瘤(RIA)是乳腺癌放疗后一种不常见但会导致死亡的并发症:放疗诱发血管肉瘤(RIA)是乳腺癌放疗后一种不常见但会导致死亡的并发症:剑桥大学医院(CUH)是英格兰东部的一个地区性治疗中心,对剑桥大学医院的乳腺放射诱发血管肉瘤患者进行了回顾性分析。诊断年龄中位数为 65 岁(41-78 岁不等)。从乳腺放疗到RIA确诊的中位时间为6.5年(范围2.4-16.0)--在过去的24年中,这一时间间隔有所缩短(r2 = 0.6601)。9%的患者在发病时已出现转移。所有患者都接受了手术(55%在中大医院,45%在当地医院)。27%的患者在一线治疗中接受了围手术期聚乙二醇脂质体多柔比星治疗。62%的患者在中位治疗28个月后复发。36%的患者出现转移,最常见的转移部位是肺部(100%)和淋巴结(50%)。所有患者的2年和5年总生存率(OS)分别为73%和60%。无进展生存期(PFS)和OS与肿瘤大小、边缘、围手术期化疗以及是否在中大医院进行手术没有相关性。与单发灶疾病相比,乳房多发灶疾病患者的术后PFS较短(中位10个月 vs 65个月;HR = 4.359 [95% CI 1.342-14.16];P = 0.0143)。年龄大于 72 岁的患者的中位 OS 为 45 个月,而年龄小于 72 岁的患者的中位 OS 为 102 个月(HR = 7.129 [95% CI 1.646-30.88];P = 0.0086):RIA的复发率和死亡率都很高,而且似乎在乳腺放疗后更早出现。结论:RIA 的复发率和死亡率都很高,而且似乎在乳腺放疗后更早发生,因此有必要对其发病机制和有效治疗方法进行进一步研究。
Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre.
Background: Radiation-induced angiosarcoma (RIA) is an uncommon but morbid complication after radiotherapy for breast cancer.
Methods: Retrospective analysis of breast RIA patients at Cambridge University Hospital (CUH), a regional treatment centre in the East of England.
Results: 22 patients were identified between 2010 and 2022. Median age of diagnosis was 65 years (range 41-78). Median time from breast radiotherapy to RIA diagnosis was 6.5 years (range 2.4-16.0)-this interval has decreased over the last 24 years (r2 = 0.6601). 9% had metastasis at presentation. All patients underwent surgery (55% at CUH, 45% at local hospitals). 27% received peri-operative pegylated liposomal doxorubicin in the first-line setting. 62% relapsed following their primary curative-intent treatments after a median of 28 months. Metastases occurred in 36%, the commonest sites being lung (100%) and lymph node (50%). 2-year and 5-year overall survival (OS) rates for all patients were 73% and 60%, respectively. No correlation between progression-free survival (PFS) and OS was found with tumour size, margin, peri-operative chemotherapy, and whether surgery was performed at CUH. Patients with multifocal disease on their breasts had shorter PFS following surgery compared to single-lesion disease (median 10 vs 65 months; HR = 4.359 [95% CI 1.342-14.16]; P = 0.0143). Patients aged > 72 years had a median OS of 45 months vs 102 months for those ≤ 72 years (HR = 7.129 [95% CI 1.646-30.88]; P = 0.0086).
Conclusion: RIA has high rates of recurrence and mortality and appears to be occurring sooner after breast radiotherapy. Further studies on its pathogenesis and effective treatment are warranted.
期刊介绍:
Breast Cancer, the official journal of the Japanese Breast Cancer Society, publishes articles that contribute to progress in the field, in basic or translational research and also in clinical research, seeking to develop a new focus and new perspectives for all who are concerned with breast cancer. The journal welcomes all original articles describing clinical and epidemiological studies and laboratory investigations regarding breast cancer and related diseases. The journal will consider five types of articles: editorials, review articles, original articles, case reports, and rapid communications. Although editorials and review articles will principally be solicited by the editors, they can also be submitted for peer review, as in the case of original articles. The journal provides the best of up-to-date information on breast cancer, presenting readers with high-impact, original work focusing on pivotal issues.